EcoDrugPlus

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSCPOG00000013127
Gene Symbol: SMO
4 Cross references
203 Possible Orthologues:

Sodium Channel Epithelial 1 Beta Subunit

Ensembl ID : ENSCPOG00000013503
Gene Symbol: SCNN1B
3 Cross references
151 Possible Orthologues:

Sodium Channel Epithelial 1 Gamma Subunit

Ensembl ID : ENSCPOG00000000029
Gene Symbol: SCNN1G
3 Cross references
155 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSCPOG00000006185
Gene Symbol: SCNN1A
2 Cross references
153 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 1

Ensembl ID : ENSCPOG00000002666
Gene Symbol: SCN1A
2 Cross references
140 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSCPOG00000013968
Gene Symbol: SCN10A
2 Cross references
302 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSCPOG00000030301
Gene Symbol: SCN11A
2 Cross references
96 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSCPOG00000002692
Gene Symbol: SCN2A
2 Cross references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSCPOG00000004367
Gene Symbol: SCN3A
2 Cross references
133 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSCPOG00000008540
Gene Symbol: SCN4A
2 Cross references
192 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSCPOG00000005240
Gene Symbol: SCN5A
4 Cross references
94 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSCPOG00000014210
Gene Symbol: SCN7A
2 Cross references
85 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).